Although there is evidence that ApoA-I may modify the anticancer immune response, detailed investigation of the effects of ApoA-I on immune checkpoints (for example programmed death ligand-1, PD-L1) in cancer cells or the cells of tumor microenvironment and on anticancer immunity has not been performed [161]. This evidence concerns the gene CD274 and cancer.